WO2006023210A3 - Gene gp132: techniques et compositions de traitement du cancer - Google Patents

Gene gp132: techniques et compositions de traitement du cancer Download PDF

Info

Publication number
WO2006023210A3
WO2006023210A3 PCT/US2005/026297 US2005026297W WO2006023210A3 WO 2006023210 A3 WO2006023210 A3 WO 2006023210A3 US 2005026297 W US2005026297 W US 2005026297W WO 2006023210 A3 WO2006023210 A3 WO 2006023210A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
mehods
treating cancer
cancer
gene
Prior art date
Application number
PCT/US2005/026297
Other languages
English (en)
Other versions
WO2006023210A2 (fr
Inventor
Ronan C O'hagan
Karuppiah Kannan
David Bailey
Murray Robinson
Original Assignee
Aveo Pharmaceuticals Inc
Ronan C O'hagan
Karuppiah Kannan
David Bailey
Murray Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Ronan C O'hagan, Karuppiah Kannan, David Bailey, Murray Robinson filed Critical Aveo Pharmaceuticals Inc
Publication of WO2006023210A2 publication Critical patent/WO2006023210A2/fr
Publication of WO2006023210A3 publication Critical patent/WO2006023210A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des techniques et des compositions permettant de traiter des états hyperprolifératifs tels qu'un cancer au moyen de réactifs associés au gène GP 132.
PCT/US2005/026297 2004-07-23 2005-07-22 Gene gp132: techniques et compositions de traitement du cancer WO2006023210A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59079104P 2004-07-23 2004-07-23
US60/590,791 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006023210A2 WO2006023210A2 (fr) 2006-03-02
WO2006023210A3 true WO2006023210A3 (fr) 2006-09-14

Family

ID=35968040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026297 WO2006023210A2 (fr) 2004-07-23 2005-07-22 Gene gp132: techniques et compositions de traitement du cancer

Country Status (1)

Country Link
WO (1) WO2006023210A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312396A1 (en) * 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
WO2008018517A1 (fr) * 2006-08-09 2008-02-14 Zeria Pharmaceutical Co., Ltd. Agent thérapeutique et/ou préventif pour une maladie s'accompagnant d'une croissance cellulaire exagérée, et polynucléotide utile en tant que principe actif

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068688A1 (fr) * 2000-03-02 2001-09-20 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine kinase humaine tak1-27, et polynucleotide codant pour ce polypeptide
WO2003037255A2 (fr) * 2001-10-31 2003-05-08 Millennium Pharmaceuticals, Inc. Procedes et compositions de diagnostic et de traitement de troubles hematologiques au moyen de 16319

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068688A1 (fr) * 2000-03-02 2001-09-20 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine kinase humaine tak1-27, et polynucleotide codant pour ce polypeptide
WO2003037255A2 (fr) * 2001-10-31 2003-05-08 Millennium Pharmaceuticals, Inc. Procedes et compositions de diagnostic et de traitement de troubles hematologiques au moyen de 16319

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EDLUND S. ET AL.: "Transforming Growth Factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated Kinase 1 and Mitogen-activated Protein Kinase Kinase 3", MOLECULAR BIOLOGY OF THE CELL, vol. 14, February 2003 (2003-02-01), pages 529 - 544, XP002387982 *
KIMURA N. ET AL.: "BMP2-induced apoptosis is mediated by activation of the TAK1-p38 Kinase pathway that is negatively regulated by SMAD6", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 23, 9 June 2000 (2000-06-09), pages 17647 - 17652, XP002387983 *
SAKURAI H. ET AL.: "Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway", THE JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 38, 19 September 2003 (2003-09-19), pages 36916 - 36923, XP002274489, ISSN: 0021-9258 *
SUN L. ET AL.: "The TRAF6 Ubiquitin Ligase and TAK1 Kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes", MOLECULAR CELL, vol. 14, 7 May 2004 (2004-05-07), pages 289 - 301, XP002387981 *
TAKAESU G. ET AL.: "TAK1 is critical for IkB Kinase-mediated activation of the NF-kB pathway", JOURNAL OF MOLECULAR BIOLOGY, vol. 326, 2003, pages 105 - 115, XP004450020 *
THIEFES A. ET AL.: "A kinase-negative mutant of the MAPK kinase TAK1 inhibits stress signalling and sensitizes NIH3T3 cells to TNF-alpha induced apoptosis", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 365, no. Suppl.1, March 2002 (2002-03-01), pages R57, XP002387984 *
ZHANG D. ET AL.: "TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice", NATURE MEDICINE, vol. 6, no. 5, May 2000 (2000-05-01), pages 556 - 563, XP002387985 *

Also Published As

Publication number Publication date
WO2006023210A2 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2006020768A3 (fr) Oligonucleotides chimiquement modifies
WO2007002204A3 (fr) Procedes de pyrosequencage et compositions associees
WO2007011962A3 (fr) Traitement du cancer
WO2007081720A3 (fr) Procédés et compositions basés sur des micro-arn et s'appliquant au diagnostic, au pronostic et au traitement du cancer du poumon
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2007079215A3 (fr) Procedes et compositions destines a eliminer l'arsenic et les metaux lourds de l'eau
WO2007127841A3 (fr) Compositions et leurs méthodes d'élaboration
WO2006072612A3 (fr) Triazolophthalazines
WO2007059041A3 (fr) Combinaisons et methodes d'utilisation d'un oligonucleotide immunomodulatoire
WO2007120980A3 (fr) Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
WO2008127290A3 (fr) Compositions d'alginate et d'alginate-lyase et procédés d'utilisation
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2006072615A3 (fr) Triazolophtalazines
WO2006088950A3 (fr) Procedes et reactifs pour le traitement et le diagnostic de la degenerescence maculaire liee a l'age
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2008013589A3 (fr) Traitement de tumeurs exprimant ras
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2006024640A3 (fr) Triazolophtalazines
WO2008112192A3 (fr) Anticorps epha3 utilises dans le traitement des tumeurs solides
WO2008027600A3 (fr) Compositions d'imatinib
WO2007127506A3 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2006132739A3 (fr) Nouveaux composes chimiques
WO2006133006A3 (fr) 1-methyl-1h-pyrazole-4-carboxamides utiles comme agents chimiotherapeutiques anticancereux
WO2005009951A3 (fr) Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation
WO2006091861A3 (fr) Compositions et methodes associees au lymphome du systeme nerveux central

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase